Global Perspectives: Current and Future State of CAR T
Impact of COVID-19 in Europe and the US. Review of new and relevant clinical advances of CAR T in DLBCL, ALL, FL, and MCL, including recently presented abstracts at ASCO and EHA.
FACULTY CO-CHAIR
Marie José Kersten, MD, PhD
Academic Medical Center – University of Amsterdam, The Netherlands
FACULTY CO-CHAIR
Frederick Locke, MD
Moffitt Cancer Center Tampa, FL, US
Faculty Members
Catherine Thieblemont, MD, PhD
Hôpital Saint-Louis, Paris, France
Martin Dreyling, MD
University of Munich Hospital, Großhadern, Germany
Paolo Corradini, MD
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Sattva Neelapu, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, US
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, US
Max Topp, MD
University Hospital, Würzburg, Germany
TOPICS COVERED IN THE REPORT
Clinical experts from across the globe discuss the impact of COVID-19 in Europe and the US and recommendations regarding the management of patients on CAR T therapy. The virtual meeting and summary report will include detailed reviews, discussion, and commentary on recent clinical advances in the use of CAR T-cell therapy in DLBCL, ALL, FL, and MCL. Key clinical data for CAR T presented at the 2020 ASCO and EHA congress meetings will be included.
For a full overview of the topics covered in the live virtual meeting and follow-up report as well as to confirm your participation in the online sessions:
